Cohen, A D <br/><br/>
Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.  [electronic resource] 

 -  Bone marrow transplantation  Jul 2002 
 - 23-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1703602  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Adolescent<br/>Adult<br/>Aminoglycosides<br/>Anti-Bacterial Agents--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Cause of Death<br/>Female<br/>Gemtuzumab<br/>Hematopoietic Stem Cell Transplantation<br/>Hepatic Veno-Occlusive Disease--chemically induced<br/>Humans<br/>Immunotoxins--administration & dosage<br/>Incidence<br/>Leukemia, Myeloid--complications<br/>Male<br/>Middle Aged<br/>Retrospective Studies<br/>Salvage Therapy<br/>Therapeutic Equivalency<br/>Treatment Outcome